Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications

MELVILLE, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces the presentation of new preclinical data at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, which took place May 6-9 in Dublin, Ireland. The data highlight the functional and proteomic differences of extracellular vesicles ("EVs"), including exosomes, derived from multiple mesenchymal stem cell ("MSC") sources.

Detailed in an oral presentation titled, "MSC Exosome Proteomics Reveal Source-Specific Therapeutic Applications," the study demonstrates that EVs derived from distinct MSC sources, including umbilical cord, brown adipose tissue, and bone marrow, exhibit unique protein signatures and biological functions that may enable targeted therapeutic and commercial applications. The data were presented on May 6, 2026.